Vicore Pharma Holding AB (publ) VCRE
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -43.63%
- 1 year
- -43.63%
- Market cap
- 257.99M
- EPS (ttm)
- -2.04
- Shares out
- 28.15M
- YTD return
- -43.63%
- 1-year return
- -43.63%
- Volume
- 11.95K
- Avg volume
- 21.50K
- Open
- 9.56
- Previous close
- 9.59
- Day's range
- 9.11 – 9.58
- 52-week range
- 7.88 – 17.80
- Beta
- 0.12
- Price target
- 35.42 (+286.7%)
- Earnings date
- Aug 21, 2026
6M -6.89 (-42.40%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -32.50%
- Free cash flow
- -241.98M
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -47.19%
- Short % of float
- 0.00%
- 50-day average
- 12.28
- 200-day average
- 12.28
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 21, 2026
Expected Aug 21, 2026. Consensus EPS estimate -0.41.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 21, 2026 | Sep 30, 2026 | -0.04211 | — | — | — |
| May 6, 2026 | Jun 30, 2026 | -0.0505 | -0.04103 | +0.01 | +18.75% |
| Feb 27, 2026 | Mar 31, 2026 | -0.04923 | -0.05843 | -0.01 | -18.69% |
| Nov 5, 2025 | Sep 30, 2025 | -0.05189 | -0.05348 | 0.00 | -3.06% |
| May 6, 2025 | Jun 30, 2025 | -0.04365 | — | — | — |
| Feb 27, 2025 | Mar 31, 2025 | -0.03211 | -0.0459 | -0.01 | -42.95% |
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Sweden
- Website
- vicorepharma.com
News
Vicore Pharma to Participate in the Chardan Healthcare Conference 
Jefferies Initiates Coverage On Vicore Pharma Holding with Buy Rating, Announces Price Target of $25 
12 Health Care Stocks Moving In Thursday's After-Market Session - 12 Health Care Stocks Moving In Wednesday's After-Market Session
Increase in Number of Shares and Votes in Vicore Pharma 
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum 
Vicore Pharma to Participate in Upcoming Healthcare Conferences 
Vicore Pharma to Present at the European Respiratory Society Congress 2026 
Evolution Metals & Technologies, Barfresh Food Group, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session 
Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on VCRE — it syncs with the Stock Master app.